Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug
Denmark’s Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel
Continua a leggere